Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Forsse D, Witteveen PO, Galaal K, van Ginkel A, Bignotti E, Weinberger V, Sweegers S, Kroep JR, Cabrera S, Snijders MPLM, Inda MA, Eriksson AGZ; European Network for Individualized Treatment in Endometrial Cancer; Krakstad C, Romano A, van de Stolpe A, Pijnenborg JMA. van Weelden WJ, et al. Among authors: kroep jr. Am J Obstet Gynecol. 2021 Oct;225(4):407.e1-407.e16. doi: 10.1016/j.ajog.2021.05.007. Epub 2021 May 19. Am J Obstet Gynecol. 2021. PMID: 34019887 Free article.
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL Study Group. Blok EJ, et al. Among authors: kroep jr. Breast Cancer Res Treat. 2018 Apr;168(2):413-420. doi: 10.1007/s10549-017-4601-1. Epub 2017 Dec 12. Breast Cancer Res Treat. 2018. PMID: 29230665 Free PMC article. Clinical Trial.
Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL and TEAM Study Groups. Blok EJ, et al. Among authors: kroep jr. Eur J Cancer. 2018 May;95:59-67. doi: 10.1016/j.ejca.2018.03.014. Epub 2018 Apr 7. Eur J Cancer. 2018. PMID: 29635145 Clinical Trial.
Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer.
Inda MA, Blok EJ, Kuppen PJK, Charehbili A, den Biezen-Timmermans EC, van Brussel A, Fruytier SE, Meershoek-Klein Kranenbarg E, Kloet S, van der Burg B, Martens JWM, Sims AH, Turnbull AK, Dixon JM, Verhaegh W, Kroep JR, van de Velde CJH, van de Stolpe A. Inda MA, et al. Among authors: kroep jr. Mol Cancer Ther. 2020 Feb;19(2):680-689. doi: 10.1158/1535-7163.MCT-19-0318. Epub 2019 Nov 14. Mol Cancer Ther. 2020. PMID: 31727690
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival.
Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW, Reyners AKL, Velu T, Goffin F, Lalisang RI, Loof NM, Boekestijn S, Krebber WJ, Hooftman L, Visscher S, Blumenstein BA, Stead RB, Gerritsen W, van der Burg SH. Melief CJM, et al. Among authors: kroep jr. Sci Transl Med. 2020 Mar 18;12(535):eaaz8235. doi: 10.1126/scitranslmed.aaz8235. Sci Transl Med. 2020. PMID: 32188726 Free article.
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Koole S, et al. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23. Int J Gynecol Cancer. 2020. PMID: 32205449 Free PMC article.
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
Post CCB, Westermann AM, Boere IA, Witteveen PO, Ottevanger PB, Sonke GS, Lalisang RI, Putter H, Meershoek-Klein Kranenbarg E, Braak JPBM, Creutzberg CL, Bosse T, Kroep JR. Post CCB, et al. Among authors: kroep jr. Gynecol Oncol. 2022 May;165(2):223-229. doi: 10.1016/j.ygyno.2022.02.025. Epub 2022 Mar 11. Gynecol Oncol. 2022. PMID: 35287967 Free article. Clinical Trial.
194 results